Abstract
We have analyzed retrospectively the records of 89 patients with Graves’ disease who were treated with radioiodine between 1980–88 and whose ophthalmopathy was recorded in a uniform manner initially and after 5 and 12 months. Moreover information on progression of eye disease was obtained by telephone for all patients after an average of 72 months. Pretreatment endocrine ophthalmopathy (class ≥ 1 of classification of American Thyroid Association) was present in 34% of the patients. Eight patients developed proptosis over 20mm, 7 patients severe ophthalmopathy (classes 4 to 6), 5 patients required special treatment for eye disease. Among the 30 patients with initial ophthalmopathy, severe ophthalmopathy (5 of 30; p < 0.05) and proptosis > 20mm 16 of 30; p < 0.05) developed in significantly more cases than in patients with no pretreatment ophthalmopathy. The data suggest that hyperthyroid patients with pretreatment ophthalmopathy are at risk for developing severe ophthalmopathy after 131I treatment.
Similar content being viewed by others
References
Werner S.C. The severe eye changes of Graves’ disease. JAMA 177: 551, 1961.
Hamilton H.E., Schultz R.O., De Growin E.L. The endocrine eye lesion in hyperthyroidism: its incidence and course in 165 patients treated for thyrotoxicosis with iodine 131. Arch. Int. Med. 105: 675, 1960.
Gorman C.A. Ophthalmopathy of Graves’ disease. N. Engl. J. Med. 308: 453, 1983.
Forrester J.V., Sutherland G.R., McDougall I.R. Dysthyroid ophthalmopathy: orbital evaluation with B-scan ultrasonography. J. Clin. Endocrinol. Metab. 45: 221, 1977.
Enzmann D., Marshall W.H., Rosenthal A.R., Kriss J.P. Computed tomography in Graves’ ophthalmopathy. Radiology 118: 615, 1976.
Wiersinga W.M., Smit T., Van der Gaag R., Mourits M., Koorneef L. Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res. 21: 73, 1989.
Shridama V., De Groot L.J. Treatment of Graves’ disease and the course of ophthalmopathy. Am. J. Med. 87: 70, 1989.
Gwinup G., Elias A.N., Ascher M.S. Effect on exophthalmos of various methods of treatment of Graves’ disease. JAMA 247: 2135, 1982.
Barnes H.V., Gann D.S. Choosing thyroidectomy in hyperthyroidism. Surg. Clin. North Am. 54: 289, 1974.
Bartalena L., Marcocci C., Bogazzi F., Panicucci M., Lepri A., Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 321: 1349, 1989.
Wyler B., Bürgi H., Probst P., Schärer K. Radiojodtherapie bei Hyperthyreose: Zuverlässigkeit eines auf dem Hausarzt und einem zentralen Register basierenden Nachkontrollschemas zur Erfassung und Behandlung der Hypothyreose. Schweiz. Med. Wochenschr. 116: 1198, 1986.
Doering P., Kramer K. Die Bestimmung des Schilddrüsengewichtes mit der Szintigraphie nach Gabe von Radiojod. Ein Beitrag zur Dosierung des Radioisotopes. Strahlentherapie 105: 245, 1958.
Werner S.C. Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J. Clin. Endocrinol. Metab. 44: 203, 1977.
Gorman C.A. Temporal relationship between onset of Graves’ ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin. Proc. 58: 515, 1983.
Wiersinga W.M., Smit T., van der Gaag R., Koornneef L. Temporal relationship between onset of Graves’ opththalmopathy and onset of thyroidal Graves’ disease. J. Endocrinol. Invest. 11: 615, 1988.
Marcocci C., Bartalena L., Bogazzi F., Panicucci M., Pinchera A. Study on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol. (Copenh.) 120: 473, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barth, A., Probst, P. & Bürgi, H. Identification of a subgroup of Graves’ disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 14, 209–212 (1991). https://doi.org/10.1007/BF03346790
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346790